Silchester International Investors Llp Has Increased Its Sk Telecom LTD (SKM) Position, 3 Analysts Bullish Summit Therapeutics PLC (ADR) (SMMT)

June 19, 2017 - By Nellie Frank

Among 4 analysts covering Summit Therapeutic (NASDAQ:SMMT), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Summit Therapeutic had 5 analyst reports since August 19, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, August 19 by Oppenheimer. The stock of Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) earned “Buy” rating by Janney Capital on Tuesday, June 21. The rating was downgraded by Zacks to “Hold” on Tuesday, September 1. RBC Capital Markets maintained it with “Outperform” rating and $29 target in Wednesday, November 16 report. The firm has “Buy” rating by H.C. Wainwright given on Friday, September 16. See Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) latest ratings:

Silchester International Investors Llp increased Sk Telecom Ltd (SKM) stake by 20.8% reported in 2016Q4 SEC filing. Silchester International Investors Llp acquired 2.81 million shares as Sk Telecom Ltd (SKM)’s stock rose 11.01%. The Silchester International Investors Llp holds 16.33M shares with $341.35 million value, up from 13.52 million last quarter. Sk Telecom Ltd now has $17.66B valuation. The stock rose 2.03% or $0.49 reaching $24.43 per share. About 90,744 shares traded. SK Telecom Co Ltd (ADR) (NYSE:SKM) has risen 24.69% since June 19, 2016 and is uptrending. It has outperformed by 7.99% the S&P500.

About 1,405 shares traded. Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) has risen 33.22% since June 19, 2016 and is uptrending. It has outperformed by 16.52% the S&P500.

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The company has market cap of $136.16 million. The Firm is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It currently has negative earnings. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI).

Among 4 analysts covering SK Telecom (NYSE:SKM), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. SK Telecom had 4 analyst reports since November 2, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, October 24 by CLSA. As per Tuesday, October 25, the company rating was downgraded by Macquarie Research. As per Wednesday, April 27, the company rating was downgraded by HSBC. As per Monday, November 2, the company rating was downgraded by JP Morgan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: